Long-term Efficacy of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-label Extension TrialB. A. Cree, K. Selmaj, L. Steinman, G. Comi, A. Bar-Or,D. L. Arnold, H. Hartung,X. Montalban,E. K. Havrdova, J. K. Sheffield,C. Cheng, J. V. Riolo,D. Silva,L. Kappos,J. A. CohenMULTIPLE SCLEROSIS JOURNAL（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
